Nycomed MRI liver imaging agent under review at FDA.
This article was originally published in The Gray Sheet
Executive Summary
NYCOMED S-095 MRI LIVER IMAGING AGENT PENDING AT FDA, Hafslund Nycomed Exec VP-R&D Trond Jacobsen said Nov. 8 at an Oppenheimer and Co. health care conference in New York City. A new drug application for the liver specific magnetic resonance imaging agent "was filed some weeks ago," Jacobsen reported. The agent allows study of "very small metastases or local lesion tumors in the liver."